Endorsements from actors like Amitabh Bachchan and Surya marks Heinz's renewed bid for a market dominated by Horlicks.
Just stand in front of his latest film Kochadaiiyaan's hoarding, send an SMS, and watch what happens next.
Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
Formal announcement of venture into new segment on Thursday; group's entry timely, given the demand, say experts
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Since August 2013, FIPB has approved two FDI proposals in the telecom sector.
Social media is the new advertising tool for today's politicians and political parties, says Viveat Susan Pinto
Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.
November IIP data show a fall of over 20%, led by automobiles, gems & jewellery and home appliances; turnaround seen as unlikely.
Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.
Company claims new use for kala jeera extract, provoking alarmed campaigners here and abroad; says reaction not based on facts.
If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
.jpg)
The Drugs Controller General of India is considering the recommendations of its advisory body to revoke the suspension of the sale of analgin-based medicines in the country.
The agency proposes to improve revenues from non-advertising segments, integrate non-traditional disciplines and strengthen sister agencies Orchard and Black Pencil.
The company has identified India as one of the two key markets in South Asia.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances